Abbotts sNDA for new six-month 45-mg formulation of Lupron Depot: FDA accepts for review
The U.S. Food and Drug Administration has accepted for review the supplemental new drug application (sNDA) of a new six-month 45-mg formulation of Lupron® Depot (leuprolide acetate for depot suspension) for use in the palliative treatment of advanced prostate cancer. Palliative treatment helps to relieve symptoms associated with advanced prostate cancer.
Leave a Response
You must be logged in to post a comment.
